ArticleAnatolian journal of cardiology2026
Hemodynamic Safety of Dexmedetomidine-Fentanyl Sedation During TAVI.
Article in Anatolian journal of cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter aortic valve implantation (TAVI) is an established alternative for patients with severe aortic stenosis who are unsuitable for surgical valve replace-ment. Conscious sedation is preferred to preserve spontaneous respiration and patient cooperation. Dexmedetomidine, a selective α2-adrenergic agonist, provides sedation, analgesia, and sympatholysis with minimal respiratory depression, making it suitable for high-risk TAVI patients.
methodsWe retrospectively analyzed 53 patients who underwent TAVI under dexme-detomidine-based sedation at a single center between January and July 2025. Patients received an initial loading dose of dexmedetomidine (1 μg/kg over 15 minutes) and fen-tanyl (1 μg/kg), followed by dexmedetomidine infusion (0.2-1.2 μg/kg/h) to achieve a Ramsay Sedation Score of 3-4 and bispectral index (BIS) 70-80. Hemodynamic param-eters were recorded at baseline (T0), post-loading (T1), 10 minutes post-loading (T2), and end of procedure (T3). Hemodynamic compromise was defined as a >30% decrease in systolic or mean arterial pressure(MAP) <65 mm Hg.
resultsThe mean age was 76.4 ± 7.3 years, with 58.5% female; all patients were ASA III-IV. Mean arterial pressure (MAP) remained above 65 mm Hg at all time points, with the greatest decrease at T2. Systolic and MAP reductions were consistently below the 30%threshold. Postoperative complications included pacemaker implantation in 2 patients, transient contrast-induced nephropathy in 1, and temporary inotropic support in 4. No anesthesia-related respiratory complications occurred.
conclusionsDexmedetomidine combined with fentanyl provides safe and effective sedation for TAVI, maintaining hemodynamic stability and spontaneous respiration. This sedation protocol minimizes perioperative risks and may improve procedural safety in high-risk patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.